Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer

References

• Lim DS, Kim JH, Lee DS, Yoon CH, Bae YS. DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors. Cancer Immunol Immunother. 2007;56(11):1817–14. doi:10.1007/s00262-007-0325-0.
   PubMed Web of Science ®Google Scholar
• Lee WC, Wang, HC, Hung, CF, Huang, PF, Lia, CR, Chen, MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005;28(5):496–504. doi:10.1097/01.cji.0000171291.72039.e2.
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973–4979. doi:10.1158/0008-5472.CAN-03-3505.
   PubMed Web of Science ®Google Scholar
• Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37(12):855–865. doi:10.1016/j.it.2016.09.006.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316(5824):608–611. doi:10.1126/science.1139253.
   PubMed Web of Science ®Google Scholar
• Thai T-H, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316(5824):604–608. doi:10.1126/science.1141229.
   PubMed Web of Science ®Google Scholar
• Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, Rodriguez A, Bradley A, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27(6):847–859. doi:10.1016/j.immuni.2007.10.009.
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Kahn D, Gibson WSJ, Round JL, Scholz RL, Chaudhuri AA, Kahn ME, Rao DS, Baltimore D. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010;33(4):607–619. doi:10.1016/j.immuni.2010.09.009.
   PubMed Web of Science ®Google Scholar
• Singh UP, Murphy AE, Enos RT, Shamran HA, Singh NP, Guan H, Hegde VL, Fan D, Price RL, Taub DD, et al. miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses. Immunology. 2014;143(3):478–489. doi:10.1111/imm.2014.143.issue-3.
   PubMed Web of Science ®Google Scholar
• Escobar T, Yu C-R, Muljo SA, Egwuagu CE. STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2013;54(6):4017–4025. doi:10.1167/iovs.13-11937.
   PubMed Web of Science ®Google Scholar
• Yao R, Ma Y-L, Liang W, Li -H-H, Ma Z-J, Yu X, Liao Y-H. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One. 2012;7(10):e46082. doi:10.1371/journal.pone.0046082.
   PubMed Web of Science ®Google Scholar
• Tsai C-Y, Allie SR, Zhang W, Usherwood EJ. MicroRNA miR-155 affects antiviral effector and effector memory CD8 T cell differentiation. J Virol. 2013;87(4):2348–2351. doi:10.1128/JVI.01742-12.
   PubMed Web of Science ®Google Scholar
• Lind EF, Elford AR, Ohashi PS. Micro-RNA 155 is required for optimal CD8+ T cell responses to acute viral and intracellular bacterial challenges. J Immunol. 2013;190(3):1210–1216. doi:10.4049/jimmunol.1202700.
   PubMed Web of Science ®Google Scholar
• Dudda JC, Salaun B, Ji Y, Palmer D, Monnot G, Merck E, Boudousquie C, Utzschneider D, Escobar T, Perret R, et al. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity. 2013;38(4):742–753. doi:10.1016/j.immuni.2012.12.006.
   PubMed Web of Science ®Google Scholar
• Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry EJ, Turner M, et al. The microRNA miR-155 controls CD8+ T cell responses by regulating interferon signaling. Nat Immunol. 2013;14(6):593–602. doi:10.1038/ni.2576.
   PubMed Web of Science ®Google Scholar
• Wang J, Iwanowycz S, Yu F, Jia X, Leng S, Wang Y, Li W, Huang S, Ai W, Fan D, et al. microRNA-155 deficiency impairs dendritic cell function in breast cancer. Oncoimmunology. 2016;5(11):e1232223. doi:10.1080/2162402X.2016.1232223.
   PubMed Web of Science ®Google Scholar
• Dunand-Sauthier I, Santiago-Raber M-L, Capponi L, Vejnar CE, Schaad O, Irla M, Seguín-Estévez Q, Descombes P, Zdobnov EM, Acha-Orbea H, et al. Silencing of c-fos expression by microRNA-155 is critical for dendritic cell maturation and function. Blood. 2011;117(17):4490–4500. doi:10.1182/blood-2010-09-308064.
   PubMed Web of Science ®Google Scholar
• Lu C, Huang X, Zhang X, Roensch K, Cao Q, Nakayama KI, Blazar BR, Zeng Y, Zhou X. miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood. 2011;117(16):4293–4303. doi:10.1182/blood-2010-12-322503.
   PubMed Web of Science ®Google Scholar
• Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008;8(5):362–371. doi:10.1038/nri2297.
   PubMed Web of Science ®Google Scholar
• Du F, Yu F, Wang Y, Hui Y, Carnevale K, Fu M, Lu H, Fan D. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2014;34(4):759–767. doi:10.1161/ATVBAHA.113.302701.
   PubMed Web of Science ®Google Scholar
• Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A. 1998;95(16):9482–9487. doi:10.1073/pnas.95.16.9482.
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Martin Kast W, Deleo AB, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1(12):1297–1302. doi:10.1038/nm1295-1297.
   PubMed Web of Science ®Google Scholar
• Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 1996;183(1):317–322. doi:10.1084/jem.183.1.317.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61(17):6451–6458.
   PubMed Web of Science ®Google Scholar
• Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002;195(10):1279–1288. doi:10.1084/jem.20012100.
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LPH, Ruiter DJ, Gerritsen MJP, Croockewit S, Britten CM, Torensma R, Adema GJ, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clini Cancer Res. 2003;9(14):5091–5100.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–146. doi:10.1038/nrc3670.
   PubMed Web of Science ®Google Scholar
• Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, Yu L, Butchar JP, Tridandapani S, Croce CM, et al. miR-155 regulates IFN-gamma production in natural killer cells. Blood. 2012;119(15):3478–3485. doi:10.1182/blood-2011-12-398099.
   PubMed Web of Science ®Google Scholar
• Zonari E, Pucci F, Saini M, Mazzieri R, Politi LS, Gentner B, Naldini L. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood. 2013;122(2):243–252. doi:10.1182/blood-2012-08-449306.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang J, Diao W, Wang D, Wei Y, Zhang C-Y, Zen K. MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol. 2014;192(3):1034–1043. doi:10.4049/jimmunol.1301309.
   PubMed Web of Science ®Google Scholar
• Chen S, Wang L, Fan J, Ye C, Dominguez D, Zhang Y, Curiel TJ, Fang D, Kuzel TM, Zhang B, et al. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res. 2015;75(3):519–531. doi:10.1158/0008-5472.CAN-14-2331.
   PubMed Web of Science ®Google Scholar
• Wang J, Yu F, Jia X, Iwanowycz S, Wang Y, Huang S, Ai W, Fan D. MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer. 2015;136(6):E602–13. doi:10.1002/ijc.29151.
   PubMed Web of Science ®Google Scholar
• Dunand-Sauthier I, Irla M, Carnesecchi S, Seguín-Estévez Q, Vejnar CE, Zdobnov EM, Santiago-Raber M-L, Reith W. Repression of arginase-2 expression in dendritic cells by microRNA-155 is critical for promoting T cell proliferation. J Immunol. 2014;193(4):1690–1700. doi:10.4049/jimmunol.1301913.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li M, Jiang Z, Wang X. A comprehensive immunologic portrait of triple-negative breast cancer. Trans Oncol. 2018;11(2):311–329. doi:10.1016/j.tranon.2018.01.011.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2013;2(10):e25771. doi:10.4161/onci.25771.
   PubMed Web of Science ®Google Scholar
• Yancey PG, Ding Y, Fan D, Blakemore JL, Zhang Y, Ding L, Zhang J, Linton MF, Fazio S. Low-density lipoprotein receptor-related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory Ly-6Chigh monocytosis: evidence that the effects are not apolipoprotein E dependent. Circulation. 2011;124(4):454–464. doi:10.1161/CIRCULATIONAHA.111.032268.
   PubMed Web of Science ®Google Scholar
• Jia X, Yu F, Wang J, Iwanowycz S, Saaoud F, Wang Y, Hu J, Wang Q, Fan D. Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs. Breast Cancer Res Treat. 2014;148(2):291–302. doi:10.1007/s10549-014-3164-7.
   PubMed Web of Science ®Google Scholar